Showing 1 - 10 of 37
We consider a follow-up study in which an outcome variable is to be measured at fixed time points and covariate values are measured prior to start of follow-up. We assume that the conditional mean of the outcome given the covariates is a linear function of the covariates and is indexed by...
Persistent link: https://www.econbiz.de/10005153096
Recently proposed double-robust estimators for a population mean from incomplete data and for a finite number of counterfactual means can have much higher efficiency than the usual double-robust estimators under misspecification of the outcome model. In this paper, we derive a new class of...
Persistent link: https://www.econbiz.de/10010568080
Persistent link: https://www.econbiz.de/10010948240
Persistent link: https://www.econbiz.de/10010947770
We consider the estimation of the parameters indexing a parametric model for the conditional distribution of a diagnostic marker given covariates and disease status. Such models are useful for the evaluation of whether and to what extent a marker's ability to accurately detect or discard disease...
Persistent link: https://www.econbiz.de/10005082025
We propose a new class of models for making inference about the mean of a vector of repeated outcomes when the outcome vector is incompletely observed in some study units and missingness is nonmonotone. Each model in our class is indexed by a set of unidentified selection-bias functions which...
Persistent link: https://www.econbiz.de/10005559416
Standardized means, commonly used in observational studies in epidemiology to adjust for potential confounders, are equal to inverse probability weighted means with inverse weights equal to the empirical propensity scores. More refined standardization corresponds with empirical propensity scores...
Persistent link: https://www.econbiz.de/10009148382
Persistent link: https://www.econbiz.de/10010605433
We present new statistical analyses of data arising from a clinical trial designed to compare two-stage dynamic treatment regimes (DTRs) for advanced prostate cancer. The trial protocol mandated that patients be initially randomized among four chemotherapies, and that those who responded poorly...
Persistent link: https://www.econbiz.de/10010605448
Persistent link: https://www.econbiz.de/10010683916